Melinda G. Gunnell

Researcher

UAMS

Also affiliated: InterveXion Therapeutics (United States) (2025)

Faculty Researcher

13 h-index 29 pubs 543 cited

Research Areas

Biomedical Subjects

Links

Lab Website

OverviewAI-generated summary

Melinda G. Gunnell's research focuses on understanding the pharmacological effects and potential treatments for substance abuse, particularly methamphetamine. Her work involves developing and testing monoclonal antibodies designed to neutralize the effects of methamphetamine, with a goal of supporting IND-enabling studies for potential therapeutic applications. Gunnell also investigates how environmental factors, such as limited bedding and nesting, can influence substance consumption, examining these effects in female rats. Her research has explored the pharmacokinetics of other substances, including α-pyrrolidinovalerophenone, in male rats, assessing the impact of vaccination strategies. Gunnell's scholarly contributions include 29 publications and a citation count of 541, with an h-index of 13. She has collaborated with several researchers at the University of Arkansas for Medical Sciences, including Michael D. Berquist, W. Brooks Gentry, Lisa K. Brents, and Brian J. Parks.

Metrics

h-index: 13
Publications: 29
Citations: 543

Selected Publications

Comparison between a chimeric anti-methamphetamine monoclonal antibody and humanized antibodies on pharmacological effects of methamphetamine (2025)

Psychopharmacology DOI OpenAlex
Identifying a Lead Candidate Anti-methamphetamine Monoclonal Antibody for IND-enabling Studies: Cross-reactivity and Locomotor Activity (2024)

Journal of Pharmacology and Experimental Therapeutics DOI OpenAlex
Limited bedding and nesting increases ethanol drinking in female rats (2024)

Pharmacology Biochemistry and Behavior 10 citations DOI OpenAlex
Pharmacokinetics of α-Pyrrolidinovalerophenone in Male Rats with and without Vaccination with an α-Pyrrolidinovalerophenone Vaccine (2021)

Journal of Pharmacy & Pharmaceutical Sciences 3 citations DOI OpenAlex
Active vaccination reduces reinforcing effects of MDPV in male Sprague-Dawley rats trained to self-administer cocaine (2020)

Psychopharmacology 3 citations DOI OpenAlex
Design, synthesis and biological evaluation of a bi-specific vaccine against α-pyrrolidinovalerophenone (α-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in rats (2019)

Vaccine 7 citations DOI OpenAlex
Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE (2019)

Drug and Alcohol Dependence 3 citations DOI OpenAlex
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats (2019)

Journal of Pharmacy & Pharmaceutical Sciences 9 citations DOI OpenAlex
Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats (2019)

Drug and Alcohol Dependence 22 citations DOI OpenAlex
Organ Distribution and Clearance of (3,4)‐Methylenedioxypyrovalerone (MDPV) Enantiomers in Female and Male Rats after Intravenous Administration of Racemic MDPV (2018)

The FASEB Journal DOI OpenAlex
Development and Preclinical Testing of a Vaccine for 3,4‐Methylenedioxypyrovalerone (( <i>R,S</i> )‐MDPV) Substance Use Disorders (2018)

The FASEB Journal DOI OpenAlex
The pharmacokinetics of racemic MDPV and its (R) and (S) enantiomers in female and male rats (2017)

Drug and Alcohol Dependence 26 citations DOI OpenAlex
Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies (2016)

Human Vaccines & Immunotherapeutics 10 citations DOI OpenAlex
Optimization of a methamphetamine conjugate vaccine for antibody production in mice (2016)

International Immunopharmacology 33 citations DOI OpenAlex
Discovery and Development of an Anti-methamphetamine Monoclonal Antibody for Use in Treating Methamphetamine Abuse (2015)

1 citation DOI OpenAlex